The startup develops targeted immunomodulator medicines that reset immune homeostasis by selectively altering the metabolic processes of dysregulated lymphocytes in patients with chronic autoimmune and inflammatory diseases. This approach enables patients to avoid chronic immunosuppression while effectively managing their conditions.
Funding
$14M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Current treatments for chronic autoimmune and inflammatory diseases often rely on broad immunosuppression, which can leave patients vulnerable to infection and other complications. These treatments may not selectively target the specific immune cells driving the disease, leading to suboptimal outcomes and potential long-term side effects.
Solution
Octagon Therapeutics is developing targeted immunomodulatory medicines designed to restore immune homeostasis in patients with chronic autoimmune and inflammatory diseases. Their approach focuses on selectively altering the metabolic processes of dysregulated lymphocytes, the immune cells that drive autoimmune pathology. By targeting glyco-immune checkpoint receptors, Octagon's therapies aim to precisely modulate disease-driving immune processes without compromising overall immune function. This selective immunomodulation strategy seeks to provide effective disease management while minimizing the risks associated with chronic immunosuppression. Octagon's lead program, OCT50, targets Siglec-2 to suppress autoreactive B cells and restore healthy immune functioning. Another program, OCT102, suppresses the secretion of inflammatory cytokines by CD8+ T cells.
Target Audience
The primary target audience includes patients suffering from autoimmune diseases such as systemic lupus erythematosus, multiple sclerosis, and Sjogren’s syndrome, as well as pharmaceutical companies seeking discovery partnerships.
Features
- Glycoproteome discovery engine to identify novel disease-driving biology
- Focus on glyco-immune checkpoint receptors for targeted immunomodulation
- OCT50: restores the endogenous role of Siglec-2, selectively suppressing autoreactive B cells
- OCT102: suppresses the secretion of inflammatory cytokines, including IL-6, IL-17, and type 1 interferon, by CD8+ T cells
- Platform enables specific targeting of disease-associated lymphocytes